Direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) infection and the risk of hepatocellular carcinoma (HCC) recurrence: A protocol for a systematic literature review First published 18/06/2021 Last updated 23/02/2022 EU PAS number:EUPAS41657 Study Finalised